Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tad A Holak

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Angewandte Chemie (International Ed. in English)|January 30, 2014
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapyAlexander Dömling, Tad A Holak
Chemmedchem|June 20, 2025
Balinatunfib: A Clinical Oral Small Molecule TNFα InhibitorAlexander Dömling, Tad A Holak
Biological Chemistry|November 4, 2006
DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 proteinMahavir Singh, Loyola D'Silva, Tad A Holak
Expert Opinion on Therapeutic Patents|March 2, 2019
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)Lukasz Skalniak, Ewa Surmiak, Tad A Holak
Structure (London, England : 1993)|December 7, 2002
Application of NMR in structural proteomics: screening for proteins amenable to structural analysisTill Rehm, Robert Huber, Tad A Holak
The Journal of Organic Chemistry|August 29, 2015
Conformations and Conformational Processes of Hexahydrobenzazocines by NMR and DFT StudiesBogdan Musielak, Tad A Holak, Barbara Rys
Cell Cycle (Georgetown, Tex.)|August 5, 2008
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domainGrzegorz M Popowicz, Anna Czarna, Tad A Holak
Angewandte Chemie (International Ed. in English)|February 23, 2011
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets seriousGrzegorz M Popowicz, Alexander Dömling, Tad A Holak
Molecules (Basel, Switzerland)|August 27, 2021
Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint AxisEdyta Zyla, Bogdan Musielak, Tad A Holak, et al.
The Journal of Biological Chemistry|August 25, 2005
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequencesMahavir Singh, Marcin Krajewski, Aleksandra Mikolajka, et al.
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Angewandte Chemie (International Ed. in English)|January 30, 2014
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapyAlexander Dömling, Tad A Holak
Chemmedchem|June 20, 2025
Balinatunfib: A Clinical Oral Small Molecule TNFα InhibitorAlexander Dömling, Tad A Holak
Biological Chemistry|November 4, 2006
DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 proteinMahavir Singh, Loyola D'Silva, Tad A Holak
Expert Opinion on Therapeutic Patents|March 2, 2019
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)Lukasz Skalniak, Ewa Surmiak, Tad A Holak
Structure (London, England : 1993)|December 7, 2002
Application of NMR in structural proteomics: screening for proteins amenable to structural analysisTill Rehm, Robert Huber, Tad A Holak
The Journal of Organic Chemistry|August 29, 2015
Conformations and Conformational Processes of Hexahydrobenzazocines by NMR and DFT StudiesBogdan Musielak, Tad A Holak, Barbara Rys
Cell Cycle (Georgetown, Tex.)|August 5, 2008
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domainGrzegorz M Popowicz, Anna Czarna, Tad A Holak
Angewandte Chemie (International Ed. in English)|February 23, 2011
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets seriousGrzegorz M Popowicz, Alexander Dömling, Tad A Holak
Molecules (Basel, Switzerland)|August 27, 2021
Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint AxisEdyta Zyla, Bogdan Musielak, Tad A Holak, et al.
The Journal of Biological Chemistry|August 25, 2005
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequencesMahavir Singh, Marcin Krajewski, Aleksandra Mikolajka, et al.
Pageof 14